Novavax (NASDAQ: NVAX) reported Q3 EPS of ($4.31), $0.40 worse than the analyst estimate of ($3.91). Revenue for the quarter came in at $178.8 million versus the consensus estimate of $334.62 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.